Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT02069912 |
Other study ID # |
USCIRB-HS-06-00420 |
Secondary ID |
CA Health Care F |
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
November 2006 |
Est. completion date |
February 2009 |
Study information
Verified date |
February 2014 |
Source |
University of Southern California |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
1. Implement an evidence-based structured care approach that includes screening; acute
treatment and relapse prevention follow-up tailored for public sector clinics and
low-income and minority patients.
2. Adapt an evidence-based collaborative care model for primary care, implement the adapted
model, evaluate and further refine the model based on the pilot experience, and produce
and disseminate a detailed manual for use in public sector clinics.
3. Evaluate Multifaceted Depression and Cardiovascular Program (MDCP) in an open trial to
determine: its acceptance by patients, medical providers, and organizational
decision-makers; patient depression treatment adherence; its direct cost; and the size
and variability of change from baseline in the primary outcome measures: depressive
symptoms, functional status, quality of life, health service use, and cardiac status at
6 and 12 month follow-up.
Description:
The pilot open trial was conducted to evaluate the effectiveness of a health services quality
improvement intervention, Multifaceted Depression and Cardiovascular Program (MDCP), on
reduction of major depressive disorder, adherence to recommended cardiac exercise and diet
self-care regimens and appointment keeping, blood pressure and low density lipid levels,
functional status, quality of life and use of health services among low-income, predominantly
Hispanic adults with congestive heart failure (CHF) or other cardiac disease such as coronary
artery disease (CAD) in public sector community-based primary care clinics. The study was
based on key observations from recent studies: 1) Patients with cardiac conditions are more
likely to experience clinically significant depressive symptoms than the general population,
with depression being associated with poor cardiac outcomes; 2) depression rates are high
among Hispanics with chronic illness; 3) Minority patients are less likely to receive care
for depression, but benefit with culturally appropriate care enhancements; and 4) depression
co-morbid with cardiac conditions is likely to be persistent. Low-income patient needs,
depression illness characteristics, and public care system resources call for a multifaceted,
collaborative chronic disease management model of depression care. MDCP is aimed at
positively affecting depression and cardiac outcomes by reducing known patient, provider, and
system barriers to care.
Participation in this study will last 12 months. All participants will first undergo baseline
assessments that will include a 40-minute interview about personal health and feelings. All
study participants will receive collaborative depression care management. They will first be
provided with information about depression treatment. Participants will then have the option
of choosing between two depression treatments: counseling or antidepressant medications.
Participants who choose to receive treatment with counseling will receive eight weekly
45-minute counseling sessions, conducted either on the phone or at the clinic. During these
sessions, participants will undergo structured problem solving therapy (PST) and will learn
strategies to manage their depressive symptoms. Participants who choose to receive treatment
with antidepressant medication will be prescribed medication by a study doctor and will be
monitored for any side effects throughout treatment. Medication treatment may last up to 12
months but will depend upon participants' severity of depression. After completing medication
treatment, participants will be offered PST counseling. All study participants will also
receive supportive patient navigation services and maintenance/relapse telephone monitoring.
All participants will undergo follow-up phone interviews about their status at months 6 and
12.